The cancer fighting group called Tempus is trying to give more help to the doctors at the University of Chicago. Eric Lefkofsky, the founder of Tempus wants breast cancer patients to have better treatments available. For this purpose Tempus and the University of Chicago have achieved a partnership.One of the most common types of cancer is breast cancer yet there is not much data accessible on the people who have fought the disease. Doctors are forced to make decisions regarding treatment without information that could aid in the process.
Genomic sequencing and machine learning are used by Tempus to help doctors make more personal decisions in the treatment of their patients. This process was started in 2015 and just recently came to light.Tempus has been setting up numerous partnerships. They work with the University of Michigan, the Robert H. Lurie Comprehensive Cancer Center, Penn Medicine, the Mayo Clinic and Rush University Medical Center in the pursuit of data that can be used in the fight against cancer.
Eric Lefkofsky is one of the founders as well as the CEO of Tempus. He was also a partner in the founding of Lightbank. This is a venture fund specializing in disruptive technologies. Mr. Lefkofsky is well known as the Chairman and co-founder of Groupon, a highly successful e-commerce website.Mr. Lefkofsky started the Lefkofsky Family Foundation in 2006 along with his wife Liz. This private charitable foundation works to advance initiatives that positively affect the lives of the people in the communities they serve. Mr. Lefkofsky is a Trustee at many worthwhile organizations. These include World Business Chicago, The Museum of Science and Industry, The Art Institute of Chicago and the Lurie Children’s Hospital of Chicago.Mr. Lefkofsky is on the board for the Chicago’s Steppenwolf Theatre Company as well as supporting the University of Chicago. In addition he has written Accelerated Disruption. Mr. Lefkofsky attended the University of Michigan where he graduated then earned his Juris Doctor in Law school.
Eric Lefkofsky, J.D., has always been an entrepreneur and a lover of technology. As the co-founder of several big-name companies like Groupon, Echo Global Logistics, and Mediaocean (to name just a few), he has a track record of pushing the limits of how society implements technology. His projects focus on using technology to increase efficiency, communication, and understanding.
With Tempus, he’s taking all that a step further. Tempus is a Chicago-based genetic sequencing company, co-founded by Lefkofsky, that wants to redefine how genomic data is used to fight cancer. Lefkofsky also serves as its CEO. Tempus’s labs don’t just collect molecular data; the company also provides a platform for that data to be analyzed in an unprecedented way. “We built a system to help physicians in clinic analyze incredible amounts of data and make real-time decisions to more effectively treat patients,” Lefkofsky said of Tempus. Tempus’s goal is to fight cancer by giving patients access to personalized treatment plans and by giving physicians the the tools that they need to analyze data effectively and share that data with others.
Now in 2017, Tempus is partnering specifically with University of Chicago Medicine to help with breast cancer research. Tempus will be sequencing and analyzing data from around 1,000 breast cancer patients. Even though breast cancer is one of the more common cancers treated by University of Chicago Medicine, professor of medicine and human genetics Dr. Olufunmilayo Olopade says that “there is relatively little accessible data on the millions of patients who have battled the disease.” Tempus wants to change that.Eric Lefkofsky and the other brilliant minds at Tempus believe that if they can help physicians and researchers uncover patterns about how breast cancer patients respond to treatment, they can help create personalized plans that are more effective for treating future patients.Tempus’s partnership with University of Chicago Medicine marks the beginning of a new era of cancer research, one which Lefkofsky hopes will make a difference in the way physicians treat breast cancer.